ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

Abraxane and Gemcitabine Improves Overall Survival

November 30, 2012

US Oncology Clarifies Role of Pharmacy Committee

January 24, 2003

Public Meeting On Ionizing Radiation Set

January 11, 1980

FDA Proposes New Nonclinical Lab Regs

November 26, 1976

Anti-NCI Forces Fail to Raid $70 Million from Cancer Program

September 26, 1975

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

May 31, 2013